S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Must-Have Silicon Companies That Don't Make Microchips
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Stocks to Benefit from the Aging Population
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Must-Have Silicon Companies That Don't Make Microchips
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Stocks to Benefit from the Aging Population
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Must-Have Silicon Companies That Don't Make Microchips
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Stocks to Benefit from the Aging Population
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Must-Have Silicon Companies That Don't Make Microchips
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Stocks to Benefit from the Aging Population
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:RPTX

Repare Therapeutics (RPTX) Stock Forecast, Price & News

$12.70
+0.51 (+4.18%)
(As of 09/25/2023 ET)
Compare
Today's Range
$12.00
$12.76
50-Day Range
$8.16
$13.01
52-Week Range
$8.02
$18.68
Volume
310,297 shs
Average Volume
114,521 shs
Market Capitalization
$534.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Repare Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
65.4% Upside
$21.00 Price Target
Short Interest
Bearish
3.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of Repare Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.45) to ($3.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

686th out of 963 stocks

Pharmaceutical Preparations Industry

309th out of 448 stocks


RPTX stock logo

About Repare Therapeutics (NASDAQ:RPTX) Stock

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.

RPTX Price History

RPTX Stock News Headlines

Repare Therapeutics (NASDAQ:RPTX) Shares Gap Up on Analyst Upgrade
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Repare Therapeutics (NASDAQ: RPTX)
Repare Therapeutics (RPTX) Receives a Buy from Bloom Burton
Repare Therapeutics (RPTX) Receives a Buy from Berenberg Bank
See More Headlines
Receive RPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RPTX Company Calendar

Last Earnings
8/09/2023
Today
9/26/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RPTX
Fax
N/A
Employees
180
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+63.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-29,050,000.00
Pretax Margin
11.23%

Debt

Sales & Book Value

Annual Sales
$131.83 million
Book Value
$6.66 per share

Miscellaneous

Free Float
30,097,000
Market Cap
$534.54 million
Optionable
Not Optionable
Beta
0.02

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Lloyd Mitchell SegalMr. Lloyd Mitchell Segal (Age 59)
    Pres, CEO & Director
    Comp: $913.39k
  • Dr. Michael Zinda Ph.D. (Age 52)
    Exec. VP & Chief Scientific Officer
    Comp: $641.53k
  • Dr. Maria Koehler M.D. (Age 66)
    Ph.D., Exec. VP & Chief Medical Officer
    Comp: $682.8k
  • Dr. Daniel Durocher Ph.D.
    Co-Founder
  • Dr. Frank Sicheri Ph.D.
    Co-Founder
  • Dr. Agnel Sfeir Ph.D.
    Co-Founder
  • Mr. Steve Forte (Age 44)
    Exec. VP & CFO
  • Mr. Daniel Belanger
    Exec. VP of Human Resource
  • Mr. Cameron Black
    Exec. VP of Discovery
  • Dr. Kim A. Seth Ph.D.
    Exec. VP & Chief Bus. Officer













RPTX Stock - Frequently Asked Questions

Should I buy or sell Repare Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RPTX shares.
View RPTX analyst ratings
or view top-rated stocks.

What is Repare Therapeutics' stock price forecast for 2023?

4 brokerages have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price forecasts range from $14.00 to $28.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 65.4% from the stock's current price.
View analysts price targets for RPTX
or view top-rated stocks among Wall Street analysts.

How have RPTX shares performed in 2023?

Repare Therapeutics' stock was trading at $14.71 at the beginning of the year. Since then, RPTX stock has decreased by 13.7% and is now trading at $12.70.
View the best growth stocks for 2023 here
.

When is Repare Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our RPTX earnings forecast
.

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) announced its earnings results on Wednesday, August, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.55. The company had revenue of $30.25 million for the quarter, compared to the consensus estimate of $7.28 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 1.14% and a negative net margin of 1.85%.

What ETF holds Repare Therapeutics' stock ?

ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AmerisourceBergen (ABC), AES (AES), Autodesk (ADSK) and

When did Repare Therapeutics IPO?

(RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

What is Repare Therapeutics' stock symbol?

Repare Therapeutics trades on the NASDAQ under the ticker symbol "RPTX."

Who are Repare Therapeutics' major shareholders?

Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (6.29%), ARK Investment Management LLC (6.24%), Sumitomo Mitsui Trust Holdings Inc. (0.77%), BlackRock Inc. (0.74%), Renaissance Technologies LLC (0.35%) and Bank of Montreal Can (0.28%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Thomas Civik and Todd Foley.
View institutional ownership trends
.

How do I buy shares of Repare Therapeutics?

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repare Therapeutics' stock price today?

One share of RPTX stock can currently be purchased for approximately $12.70.

How much money does Repare Therapeutics make?

Repare Therapeutics (NASDAQ:RPTX) has a market capitalization of $534.54 million and generates $131.83 million in revenue each year. The company earns $-29,050,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Repare Therapeutics have?

The company employs 180 workers across the globe.

How can I contact Repare Therapeutics?

Repare Therapeutics' mailing address is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. The official website for the company is www.reparerx.com. The company can be reached via phone at 857-412-7018 or via email at investor@reparerx.com.

This page (NASDAQ:RPTX) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -